MORE™ is Trekka's patent-pending multi-layer oral wafer. Dissolves on the tongue, buccal mucosa, or sublingually — no water required. A highly tunable layer architecture — active APIs, taste masking, extended release, tunable mucoadhesion, and optional CAPRO™-enhanced solubilization when the API calls for it. One platform. OTC to market fast. Rx value long-term.
The elderly struggle with swallowing. Children resist tablets. Patients with dysphagia, dry mouth, or post-surgical conditions cannot take conventional pills reliably. Poor adherence follows — and outcomes fall short of what the drug can actually do.
| Delivery criterion | Conventional pill / tablet | MORE™ oral wafer |
|---|---|---|
| Water requirementAdministration barrier | Requires water and swallowing — excludes elderly, pediatric, dysphagia patients and many care settings | Dissolves on the tongue in seconds — no water, no swallowing, no administration barrier |
| Adherence rateReal-world compliance | Up to 50% of patients skip or miss daily oral medications — the format itself drives non-adherence | Convenient, discreet, water-free — removes the primary compliance barrier for daily oral therapy |
| Absorption routeOnset and PK variability | GI absorption — slow, variable, subject to food effects and first-pass hepatic metabolism | Transmucosal absorption — bypasses GI and first-pass, faster onset, more consistent systemic exposure |
| Release profilePK programmability | Single release profile — fast-dissolve OR extended, not both. One API per conventional tablet practical limit. | Tunable multi-layer architecture — fast, extended, or biphasic from a single wafer, with multiple APIs independently controlled |
| Poorly soluble APIsBCS II / IV formulation | Standard oral excipients offer limited solubility enhancement — BCS IV molecules often not viable as tablets | Optional CAPRO™-enhanced layers available when the API requires solubilization support — not a requirement for every formulation |
| Market reachOTC and Rx addressability | Tablets can serve either OTC or Rx — the same platform rarely spans both markets with meaningful differentiation | Identical platform — OTC generates near-term revenue, Rx builds clinical IP. Both from one technology investment. |
The entire delivery sequence is designed to eliminate every friction point a conventional oral dose form creates.
Every capability is a direct answer to a documented limitation of tablets, capsules, and oral liquids.
MORE™ is a complete oral delivery platform on its own. For APIs that require solubilization support — BCS Class II/IV molecules, poorly soluble drugs — CAPRO™-enhanced layers can be incorporated. The combination delivers tunability no competing platform can match.
MORE™ is best suited where delivery speed, patient convenience, and format differentiation are clinically or commercially meaningful.
Reformulating an approved API into a MORE™ wafer qualifies for 505(b)(2) because the active ingredient is unchanged. Every Rx MORE™ program is designed around this from first molecule evaluation.